Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01821118 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
A Phase 2 study of Cerebral Amyloid Angiopathy, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 13
- Study locations
NCT01821118 is a Phase 2 study of Cerebral Amyloid Angiopathy that has completed, run by Pfizer. The registered enrollment target is 36 participants. The trial reports 13 study locations across 9 states.
The verdict
NCT01821118, a Phase 2 study of Cerebral Amyloid Angiopathy, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 13
- Study locations
Study Summary
Cerebral Amyloid Angiopathy (CAA) is a condition caused by the build-up of a protein called amyloid, predominantly Aβ40, within the walls of brain blood vessels, especially those blood vessels in the occipital lobe of the brain. Probable CAA may be defined as two or more hemorrhages in the brain cortex in individuals 55 years of age or older. This study will examine the study drug (PF-04360365) vs. placebo (saline) at 10 mg/kg - Day 1 and the maintenance dose of the study drug (PF-04360365) vs. placebo (saline) at 7.5mg/kg on Days 30 and 60. Subjects will be followed for 6 months after receiving the last dose of study medication.
Conditions Studied
Interventions
- OTHER placebo
- BIOLOGICAL Ponezumab
Study Locations (13)
Massachusetts
- MGH Stroke Research Center - Boston
- Boston Medical Center - Menino Pavilion - Boston
- Boston Medical Center - Shapiro Center - Boston
- Anthinoula A. Martinos Center for Biomedical Imaging - Charlestown
NAP
- CHRU de Lille - Hôpital Roger Salengro - Lille
- CHRU de Lille - Lille
California
- UCLA Ronald Reagan Medical Center - Los Angeles
Missouri
- Barnes Jewish Hospital - St Louis
New York
- Columbia University - New York
Alberta
- University of Calgary/Foothills Medical Centre - Calgary
Ontario
- Sunnybrook Health Sciences Centre - Toronto
Utrecht
- University Medical Center Utrecht - Utrecht
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01821118
The ClinicalTrials.gov registry entry for NCT01821118 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cerebral Amyloid Angiopathy appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01821118 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Massachusetts, NAP, California.
Frequently Asked Questions
What is clinical trial NCT01821118 about?
NCT01821118 is a clinical study titled "Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy". Cerebral Amyloid Angiopathy (CAA) is a condition caused by the build-up of a protein called amyloid, predominantly Aβ40, within the walls of brain blood vessels, especially those blood vessels in the occipital lobe of the brain. Probable CAA may be defined as two or more hemorrhages in the brain cor...
What is the current status of trial NCT01821118?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2013-06. Estimated completion is 2015-09.
What conditions does trial NCT01821118 study?
This clinical trial studies the following conditions: Cerebral Amyloid Angiopathy.
What interventions are being tested in trial NCT01821118?
The interventions under investigation include: placebo (OTHER), Ponezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01821118?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01821118 being conducted?
This trial has 13 study locations across California, Massachusetts, Missouri, New York, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Amyloid Angiopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.